
Please try another search
Oncolys BioPharma Inc. is a biopharmaceutical company. The Company operates in two business segments. Pharmaceutical business segment is engaged in the research, development, manufacture and marketing of pharmaceuticals. Diagnostic reagents business segment is engaged in the research, development, manufacture and marketing of diagnostic reagents and equipment, as well as the provision of inspection service. The Company's main pipeline includes OBP-301 (Telomelysin), an oncolytic virus; OBP-801, an epigenetic anticancer drug and OBP-601 for the treatment of human immunodeficiency virus (HIV) infection, among others.
Name | Age | Since | Title |
---|---|---|---|
Naoko Iino | 64 | 2023 | Independent Outside Director |
Takahito Yanagisawa | - | 2025 | Outside Auditor |
Masaya Nagasue | - | 2025 | Outside Auditor |
Yasuo Urata | 70 | 2004 | Chairman, CEO & President |
Toru Saito | 68 | 2022 | Independent Outside Director |
Shinichi Kyuse | 66 | 2025 | Full Time Corporate Auditor |
Yasunari Kashihara | 60 | 2008 | Managing Director & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review